On November 26, an enterprise representative who walked out of the centralized insulin procurement site revealed that Ganli Pharmaceutical’s insulin glargine injection was quoted at 48.71 yuan, and the other insulin aspart was quoted at about 19 yuan. A total of two products have won the bid.
Minenet data shows that in 2020, the sales of terminal insulin and similar drugs in public medical institutions in China will be close to 27 billion yuan. The total market share of the three foreign companies exceeds 70%. In terms of domestic enterprises, Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are the leaders. Among them, Ganli Pharmaceutical’s insulin market share will exceed 10% in 2020.
Today, the National Medical Insurance Bureau is in Shanghai to carry out the sixth batch of national-organized drug centralized procurement work. This time it is a special procurement of insulin. Calculated based on the demand put forward by 32,000 medical institutions, the demand for centralized insulin collection is about 200 million, and the amount involved is about 17 billion yuan, which is related to the well-being of 10 million insulin patients nationwide. This morning, the bidding and bid opening work of insulin manufacturers will be carried out, and the results of the selection will be announced later.